FTRE
Fortrea Holdings Inc. Health Care Services-Medical Laboratories Russell 3000
$21.29Close
$2.0BMarket cap
$8.87 – $25.8852-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 92 · stronger than 92% of stocks over 12 months
Cautions
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
18%
1wk
down 9.9%
price change
1mo
up 6.7%
price change
12-month return
up 112%
market up 11% ·
its own up 93%
F-score
—
— Not assessed
Altman Z″
-3.58
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.5×
price / book
Earnings yield
down 30.6%
EBIT / enterprise value
Cheaper than
37%
of the market · expensive
Revenue growth
up 1%
year on year
EPS growth
—
latest quarter
Sales growth
down 1%
latest quarter · +3 pts
ROE
down 103%
return on equity
Free cash margin
up 3%
$88.3M FCF
D/E
1.86
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-5% then +1%)
Trade setup
ATR%
6.8%
$1.44 a day · 2×ATR $18.41
RS
92 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.7×
vs 50-day average
Up/down volume
1.16
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 3.8% over the year, from 90m to 93m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 29, 2026
Last shock
Oct 29, 2026-11% in one session3.0× volumeon results-8% since
Financials
- Net -36%
- Free cash 3%
- Cash
- Long-term debt
| FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|
| Revenue | $3.1B | $2.8B | $2.8B | $2.7B | $2.7B |
| Operating income | $114.3M | $187.1M | $32.0M | -$161.9M | -$872.6M |
| Net income | $98.0M | $186.2M | -$25.0M | -$329.0M | -$989.0M |
| Net margin | 3% | 7% | -1% | -12% | -36% |
| Earnings per share | $1.10 | $2.10 | -$0.28 | -$3.68 | — |
| Free cash flow | $143.3M | $28.3M | $128.1M | $237.3M | $88.3M |
| Free cash margin | 5% | 1% | 5% | 9% | 3% |
| Cash | $94.6M | $112.0M | $108.6M | $118.5M | $174.6M |
| Long-term debt | — | $0 | $1.6B | $1.0B | $1.0B |
| Shareholders' equity | $3.3B | $3.3B | $1.7B | $1.4B | $563.5M |
| Shares outstanding | — | 0 | 88.80m | 89.70m | 93.10m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 29, 2026 | Quarterly ↗ | Jun 30, 2026 | 29d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 24, 2024 | Quarterly ↗ | Mar 31, 2024 | 54d |
| Mar 13, 2024 | Annual ↗ | Dec 31, 2023 | 73d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Sep 30, 2026 | Director or officer change ↗ |
| Sep 10, 2026 | Director or officer change ↗ |
| Jul 29, 2026 | Results · Director or officer change ↗ |
| Jul 14, 2026 | Director or officer change ↗ |
| Jun 26, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Feb 26, 2026 | Results ↗ |
| Nov 20, 2025 | Regulation FD ↗ |
| Nov 5, 2025 | Results ↗ |
| Sep 22, 2025 | Director or officer change · Regulation FD ↗ |